Drugs in Dev.
Infections and Infectious Diseases
Phase III
Netherlands 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sabin Strain Based Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Sinovac Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval of Sinovac’s polio vaccine (sIPV) by the NMPA in China is a major milestone in the ongoing efforts towards global polio eradication & to reduce the vaccine-associated paralytic polio caused by oral polio vaccines, which are based on live a...
Product Name : sIPV
Product Type : Vaccine
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : Sabin Strain Based Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Sinovac Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Human Alkaline Phosphatase
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial
Details : The REVIVAL trial is a Phase III pivotal study evaluating AM-Pharma’s proprietary recombinant alkaline phosphatase, ilofotase alfa, for the treatment of patients with SA-AKI.
Product Name : Ilofotase Alfa
Product Type : Enzyme
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : Recombinant Human Alkaline Phosphatase
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sabin Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Intravacc’s Sabin-IPV Vaccine Eupolio Receives WHO Prequalification to Treat Poliomyelitis
Details : Eupolio was developed by Intravacc for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative. Eupolio™ received the prequalification status from the WHO by the end of December...
Product Name : Eupolio
Product Type : Vaccine
Upfront Cash : Inapplicable
January 21, 2021
Lead Product(s) : Sabin Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine
Details : Under the agreement, HALIX will provide commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands. To meet the increased demand, HALIX expands with two additional viral vector produ...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 08, 2020
Lead Product(s) : ChAdOx1 nCoV-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bivalent Oral Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Serum Institute of India
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals
Details : Bivalent Oral Polio Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Poliomyelitis.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 10, 2016
Lead Product(s) : Bivalent Oral Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Serum Institute of India
Deal Size : Inapplicable
Deal Type : Inapplicable
